Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-30T00:55:52.226Z Has data issue: false hasContentIssue false

Chapter 7 - Tardive dyskinesia treatment

Published online by Cambridge University Press:  05 July 2015

Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schonecker, M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957;28:550553.Google ScholarPubMed
Goldberg, RJ. Tardive dyskinesia in elderly patients: an update. J Am Med Dir Assoc. 2002;3(3):152161.CrossRefGoogle ScholarPubMed
Faurbye, A, Rash, PJ, Petersen, PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scan. 1964;40:1027.CrossRefGoogle ScholarPubMed
Fernandez, HH, Friedman, JH. Classification and treatment of tardive syndromes. Neurologist. 2003;9:1627.CrossRefGoogle ScholarPubMed
Waln, O, Jankovic, J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 2013;3:110.Google ScholarPubMed
Bhidayasiri, R, Boonyawairoj, S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87:132141.CrossRefGoogle ScholarPubMed
Orti-Pareja, M, Jimenez-Jimenez, FJ, Vasquez, A, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord. 1999;5:5965.CrossRefGoogle ScholarPubMed
Mehanna, R, Jankovic, J. Respiratory disorders associated with dystonia. Mov Disord. 2012;27:18161819.CrossRefGoogle ScholarPubMed
Kane, JM, Smith, JM. Tardive dyskinesia: Prevalence and risk factors 1959–1979. Arch Gen Psychiatry. 1982;39:473481.CrossRefGoogle Scholar
Tarsy, D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589598.CrossRefGoogle ScholarPubMed
Ragheb, MM, Goldberg, RJ. Tardive Dyskinesia in geriatric patients. Aging Health. 2006;2(5):833849.CrossRefGoogle Scholar
Dilsaver, SC, Greden JF. Possible cholinergic mechanism in reserpine and tardive dyskinesia. Am J Psychiatry. 1984 Jan;141(1):151–2.Google ScholarPubMed
Tamminga, CA, Thaker, GK, Nguyen JA. GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism. Psychopharmacol Bull. 1989;25(1):43–6 (Review).Google ScholarPubMed
Lister, J, Nobrega, JN, Fletcher, PJ, Remington, G.Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology (Berl). 2014 Jun;231(11):2237–49.CrossRefGoogle ScholarPubMed
Schooler, NR, Kane, JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982 Apr;39(4):486–7.Google ScholarPubMed
American Psychiatric Association. Differential diagnosis of tardive dyskinesia. In: Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington DC: The Association; 1980:2122.Google Scholar
Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151156.CrossRefGoogle ScholarPubMed
Bakker, PR, de Groot, IW, van Os, J, et al. Long-stay psychiatry patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One 2011;6:e25588.CrossRefGoogle Scholar
Miller, DD, Caroff, SN, Davis, SM, et al. Extrapyramidal side-effects of antipsychotics in a randomized trial. Br J. Psychiarty 2008;193:279288.CrossRefGoogle Scholar
Glazer, WM, Morgenstern, H, Schooler, N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J. Psychiatry 1990;157:585592.CrossRefGoogle ScholarPubMed
Egan, MF, Apud, J, Wyatt, RJ. Treatment of tardive dyskinesia. Schizophrenia Bulletin. 1997;23(4):583609.CrossRefGoogle ScholarPubMed
Pantanwala, AE, Amini, R, Hays, DP, et al. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010;39(3):330336.CrossRefGoogle Scholar
Rana, AQ, Chaudry, ZM, Blanchet, PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug, Design, Development and Therapy. 2013;7:13291340.CrossRefGoogle ScholarPubMed
Soares-Weiser, K, Mobsy, C, Holliday, E. Anticholinergic medication for neuroleptic-induced tardive dyskinesia (Review). The Cochrane Library. 1997:2. Retrieved from www.thecochranelibrary.com.Google Scholar
DeSmedt, T, Raedt, R, Vonck, K, Boon, P. Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Reviews. 2007;13(1):5778.CrossRefGoogle Scholar
Jankelowitz, SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:13711380.CrossRefGoogle ScholarPubMed
Cloud, LJ, Zutshi, D, Factor, S. Tardive dyskinesia: Therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11:166176.CrossRefGoogle ScholarPubMed
Woods, SW, Saksa, JR, Baker, CB, Chen, SJ, Tek, C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo controlled study. J Clin Psychiatry. 2008: 69(4):546554.CrossRefGoogle ScholarPubMed
Libov, I, Miodownik, C, Bersudsky, Y, Dwolatzky, T, Lerner, V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: A randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(7):10311037.CrossRefGoogle ScholarPubMed
Iwata, Y, Irie, S, Ulchida, H, Suzuki, T, Watanabe, K, Iwashita, S, Mimura, M. Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. J Neurol Sci. 2012;315:137140.CrossRefGoogle ScholarPubMed
Schrodt, GR, Wright, JH, Simpson, R, Moore, DP, Chase, S. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):328331.Google ScholarPubMed
Wilbur, R, Kulik, F. Propranolol (inderal) for tardive dyskinesia and extrapyramidal side effects from neuroleptics: Possible involvement of beat – adrenergic mechanisms. Prog Neuropsychopharmacol. 1981;4(6):627632.CrossRefGoogle Scholar
Perenyi, A, Farkas, A. Propranolol in the treatment of tardive dyskinesia. Biol Psychiatry. 1983;18:391394.Google ScholarPubMed
Factor, SA. Propranolol therapy for tardive dyskinesia revisited. Mov Dis. 2012;27(13):1703.CrossRefGoogle Scholar
Cowen, MA, Green, M, Bertollo, DN, Abbott, K. A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol. 1997;17(3):190193.CrossRefGoogle ScholarPubMed
Bhidayasiri, R, Fahn, S, Weiner, WJ, Gronseth, GS, Sullivan, K, Zesiewicz, T. Evidence-based guideline: Treatment of tardive syndromes. Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81:463469.CrossRefGoogle Scholar
Suddath, RL, Straw, GM, Freed, WJ, Bigelow, LLB, Kirch, D, Wyatt, RJ. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav. 1991;39:743745.CrossRefGoogle ScholarPubMed
Pham, DQ, Plakogiannis, R. Vitamin E supplementation in Alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother 2005;39:20662068.Google ScholarPubMed
Zhang, WF,Tan, YL, Zhang, XY, Chan, RC, Wu, HR, Zhou, DF. Extract of ginkgo biloba treatment for tardive dyskinesia in schizophrenia a randomized, double blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615621.CrossRefGoogle ScholarPubMed
Adler, LA, Rotrosen, J, Edson, R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836841.CrossRefGoogle Scholar
Lam, LC, Chiu, HF, Hung, SF. Vitamin E in the treatment of tardive dyskinesia: a replication study. J Nerv Ment Dis. 1994;182:113114.CrossRefGoogle ScholarPubMed
Shriqui, CL, Bradwejn, J, Annable, L, Jones, BD. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. Am J Psychiatry. 1992;149:391393.Google ScholarPubMed
Schmidt, M, Meister, P, Baumann, P. Treatment of tardive dyskinesia with vitamin E. Eur Psychiatry. 1991;6:201207.CrossRefGoogle Scholar
Nelson, LA, McGuire, JM, Hausafus, SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother 2003;37:11281131.CrossRefGoogle ScholarPubMed
Shamir, E, Barak, Y, Plopsky, I, Zisapel, N, Elizur, A, Weizman, A. Is melatonin effective for tardive dyskinesia? J Clin Psychiatry. 2000;61:556558.CrossRefGoogle ScholarPubMed
Shamir, E, Barak, Y, Shalman, I, et al. Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58:10491052.CrossRefGoogle ScholarPubMed
Richardson, MA, Small, AM, Read, LL, Chao, HM, Clelland, JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry 2004;65(1):9296.CrossRefGoogle ScholarPubMed
Richardson, MA, Bevans, ML, Read, LL, et al. Efficacy of the branch chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160(6):11171124.CrossRefGoogle ScholarPubMed
Lerner, V, Miodownik, C, Kaptsan, A, Cohen, H, Matar, M, Lowenthal, U, Kolter, M. Vitamin B6 in the treatment of tardive dyskinesia: A double blind placebo-controlled crossover study. Am J Psychiatry 2001;158:15111514.CrossRefGoogle ScholarPubMed
Lerner, V, Miodownik, C, Kaptsan, A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):16481654.CrossRefGoogle ScholarPubMed
Grohmann, R, Koch, R, Schmidtd, LG. Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl. 1990;29:7182.Google ScholarPubMed
Ross, RT. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci. 1990 May;17(2):155162.CrossRefGoogle ScholarPubMed
Cookson, JC. Side effects during long-term treatment with depot anti-psychotics Clin Neuropharm. 1991;14(S2):S24-S30.Google Scholar
Lauterbach, EC. Haloperidol-induced dystonia and parkinsonism in discontinuing metoclopramide: implications for differential thalamocortical activity. J Clin Psychopharmacol. 1992;12(6):442443.CrossRefGoogle ScholarPubMed
Chouinard, G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15: (Suppl 1):36S-44S.CrossRefGoogle ScholarPubMed
Bai, YM, Yu, SC, Lin, CC. Risperidone for severe tardive dyskinesia: A 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:13421348.CrossRefGoogle ScholarPubMed
Chan, HY, Chiang, SC, Chang, CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry. 2010;71:12261233.CrossRefGoogle ScholarPubMed
Dalack, GW, Becks, L, Meador-Woodruff, JH. Tardive dyskinesia, clozapine and treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(4):567573.CrossRefGoogle ScholarPubMed
Simpson, GM, Lee, JH, Shrivastava, RK. Clozapine in tardive dyskinesia. Psychopharmacology. 1978;56:7580.CrossRefGoogle ScholarPubMed
Littrel, K, Magill, AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv. 1993;31(9):1418.CrossRefGoogle Scholar
Bassitt, DP, Louza Neto, MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998;248:209211.CrossRefGoogle ScholarPubMed
Gerlach, J, Koppelhus, P, Helweg, E, Monrad, A. Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand. 1974;50:410424.CrossRefGoogle Scholar
Kinon, BJ, Jeste, DV, Kollack-Walker, S, Stauffer, V, Liu-Seifert, H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:985996.CrossRefGoogle ScholarPubMed
Na-Ri, K, Moon-Doo, K. Tardive dyskinesia: Treatment with aripiprazole. Clin Psychopharmacol Neurosci. 2011;9(1):18.Google Scholar
Tammenmaa, IA, Sailas, E, McGrath, JJ, Soares-Weiser, K, Wahlbeck, K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:10991107.CrossRefGoogle ScholarPubMed
Caroff, SN, Campbell, EC, Havey, JC, SullivanKA, , Katz, IR, Mann, SC. Treatment of tardive dyskinesia with donepezil. J Clin Psychiatry. 2001;62(2):128129.CrossRefGoogle ScholarPubMed
Kazamatsuri, H, Chien, CP, Cole, JO. Treatment of tardive dyskinesia: clinical efficacy of a dopamine-depleting agent, tetrabanzine. Arch Gen Psychiatry. 1972;27:9599.CrossRefGoogle Scholar
Ondo, WG, Hanna, PA, Jankovic, J. Tetrabenzine treatment for tardive dyskinesia: Assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):12791281.CrossRefGoogle Scholar
Guay, DR. Tetrabenzaine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331373.CrossRefGoogle Scholar
Chen, JJ, Ondo, WG, Dashtipour, K, Swope, DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):14871504.CrossRefGoogle ScholarPubMed
Huang, CC, Wang, RIH, Hasegawa, A, et al. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology. 1981;73:359362.CrossRefGoogle ScholarPubMed
Goff, DC, Renshaw, PF, Sarid-Segal, O, Dreyfuss, DA, Amico, ET, Ciraulo, DA. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry. 1993;33(10):700706.CrossRefGoogle ScholarPubMed
Lieberman, JA, Alvir, J, Mukherjee, S, Kane, JM. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry. 1989;46(10):908913.CrossRefGoogle ScholarPubMed
Stewart, RM, Rollins, J, Beckham, B, Roffman, M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol 1982;5:365373.CrossRefGoogle ScholarPubMed
Gerlach, J, Rye, T, Kristjansen, P. Effect of baclofen on tardive dyskinesia. Psychopharmacology (Berl). 1978;56:145151.CrossRefGoogle ScholarPubMed
Glazer, WM, Moore, DC, Bowers, MB, Bunney, BS, Roffman, M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology (Berl). 1985;87:480483.CrossRefGoogle ScholarPubMed
Thaker, GK, Nguyen, JA, Strauss, ME, Jacobson, R, Kaup, BA, Tamminga, CA. Clonazepam treatment of tardive dyskinesia: A practical GABA mimetic strategy. Am J Psychiatry. 1990;147(7):445451.Google Scholar
Yung, C. Case vignettes of movement disorders. Brain Res Bull. 1983;11:191194.CrossRefGoogle ScholarPubMed
Angus, S, Sugars, J, Boltezar, R, Koskewich, S, Schneider, N. A Controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17(2):8891.CrossRefGoogle ScholarPubMed
Pappa, S, Tsouli, S, Apostolou, G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271275.CrossRefGoogle ScholarPubMed
Tschopp, L, Salazar, Z, Micheli, F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol. 2009;32(3):165166.CrossRefGoogle ScholarPubMed
Slotema, CW, van Harten, PN, Bruggeman, R, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507509.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×